Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Arbuck, SG (1996) Workshop on phase I study design. Ann Oncol 7: 567–573.
Collins, JM, Zaharko, DS, Dedrick, RL & Chabner, BA (1986) Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 70: 73–80.
Collins, JM, Grieshaber, CK & Chabner, BA (1990) Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst 82: 1321–1326.
DeGeorge, JJ, Ahn, C-H, Andrews, PA, Brower, ME, Giorgio, DW, Goheer, ME, Lee-Ham, DY, McGuinn, WD, Schmidt, W, Sun, CJ & Tripathi, SC (1998) Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol 41: 173–185.
Dent, SF & Eisenhauer, EA (1996) Phase I trial design: are new methodologies being put into practice?. Ann Oncol 7: 561–566.
Fox, BW (1998) The history of radium in medicine in Manchester. Clin Oncol 10: 115–124.
Freireich, EJ, Gehan, EA, Rall, DP, Schmidt, LH & Skipper, HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother Rep 50: 219–244.
Goldsmith, MA, Slavik, M & Carter, SK (1975) Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res 35: 1354–1364.
Grieshaber, CK & Marsoni, S (1986) Relationship of preclinical toxicology to finding in early clinical trials. Cancer Treat Rep 70: 65–72.
Homan, ER (1972) Quantitative relationships between toxic doses of antitumour chemotherapeutic agents in animals and man. Cancer Chemother Rep Part 3: 13–19.
Penta, JS, Rozencweig, M, Guarino, AM & Muggia, FM (1979) Mouse and large-animal toxicology studies of twelve antitumour agents: relevance to starting dose for phase I clinical trials. Cancer Chemother Pharmacol 3: 97–101.
Penta, JS, Rosner, GL & Trump, DL (1992) Choice of starting dose and escalation for phase I studies of antitumour agents. Cancer Chemother Pharmacol 31: 247–250.
Ratain, MJ, Mick, R, Schilsky, RL & Siegler, M (1993) Statistical and ethical issues in the design and conduct of phase I and phase II clinical trials of new anticancer agents. J Natl Cancer Inst 85: 1637–1643.
Rozencweig, M, VonHoff, DD, Staquet, MJ, Schein, PS, Penta, JS, Goldin, A, Muggia, FM, Freireich, EJ & DeVite, VT (1981) Animal toxicology for early clinical trials with anticancer agents. Cancer Clin Trials 4: 21–28.
Simon, R, Freidlin, B, Rubinstein, L, Arbuck, S, Collins, J & Christain, MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89: 1138–1147.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Leyland-Jones, B., Grieshaber, C. Of (only) mice and men. Br J Cancer 81, 753–755 (1999). https://doi.org/10.1038/sj.bjc.6690759
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690759
